Prosecution Insights
Last updated: November 04, 2026

Sabanci Üniversitesi

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Analysis

Sabanci Üniversitesi has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is located within a distinct art unit, reflecting a focused technical scope for the university's current patent activity. The prosecution is handled by 1 distinct examiner, which centralizes the communication and negotiation process between the applicant and the patent office. This focused approach is typical for portfolios with limited active filings, where the goal is to resolve the outstanding matter efficiently through a single point of contact.

The busiest examiner, SKELDING, ZACHARY S, is responsible for the pending office action. Since this is the only pending action in the portfolio, the examiner's individual review will determine the immediate path forward for the university's intellectual property. This single-examiner environment simplifies the prosecution strategy by removing the need to reconcile different examiner viewpoints or art unit practices. Practitioners should prioritize a clear and direct dialogue with SKELDING, ZACHARY S to address any technical rejections or prior art concerns raised in the 1 distinct art unit.

The presence of a distinct art unit in the Biotechnology & Pharmaceuticals field indicates that the technology is being evaluated by a specific group of experts. Because there is only 1 pending office action, the practitioner can focus exclusively on the concerns of the assigned examiner. This concentrated effort is beneficial for ensuring a thorough and effective response to the patent office's requirements. Success in this matter will secure the university's position in the life sciences sector and provide a foundation for future research commercialization.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
0
Medium (0%)
1
Easy (100%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SKELDING, ZACHARY S 1 59.8% +41.1%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18464643 NATURAL KILLER (NK) CELLS EXPRESSING AN ANTIGEN-SPECIFIC FUNCTIONAL T CELL RECEPTOR (TCR) COMPLEX, METHODS FOR PRODUCTION THEREOF, AND METHODS FOR THERAPEUTIC USE THEREOF SKELDING, ZACHARY S —

Top Art Units

Art UnitApps
1644 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18464643 NATURAL KILLER (NK) CELLS EXPRESSING AN ANTIGEN-SPECIFIC FUNCTIONAL T CELL RECEPTOR (TCR) COMPLEX, METHODS FOR PRODUCTION THEREOF, AND METHODS FOR THERAPEUTIC USE THEREOF SKELDING, ZACHARY S 1644 §112Other Non-Final OA — Pending Sep 11, 2023

Managing Sabanci Üniversitesi's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Sabanci Üniversitesi have?

Sabanci Üniversitesi has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Sabanci Üniversitesi applications?

Zachary S Skelding has the most, with 1 of Sabanci Üniversitesi's pending office actions.

What technology area are Sabanci Üniversitesi's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month